Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRATUS: Pomalidomide + Low-Dose Dexamethasone in RRMM
NCT01712789Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2012
- Primary completion
- Dec 2019
- Modality
- Molecular Glues
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Treatment Emergent Adverse Events. Started Nov 2012; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01712789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712789.